|
European patients need improved access to biosimilar medicines |
Medicines for Europe |
22 Apr 2021 |
Health & Consumers |
|
New report assesses progress on biosimilar medicine policies across Europe |
Medicines for Europe |
30 Mar 2021 |
Health & Consumers |
|
EU industrial policy can dramatically improve medicines manufacturing resilience and security of supply |
Medicines for Europe |
17 Mar 2021 |
Health & Consumers |
|
New report reveals need for pricing and reimbursement and procurement reforms to ensure patient access and healthcare sustainability |
Medicines for Europe |
01 Mar 2021 |
Health & Consumers |
|
Smart policies will encourage more critical medicines manufacturing in Europe |
Medicines for Europe |
26 Feb 2021 |
Health & Consumers |
|
EU must address barriers to continuous off-patent innovation and grasp opportunity for patients and healthcare |
Medicines for Europe |
23 Feb 2021 |
Health & Consumers |
|
A new medicines trade and health security agenda for the European Commission |
Medicines for Europe |
19 Feb 2021 |
Health & Consumers |
|
No further excuse to delay digital regulatory infrastructure for medicines after COVID-19 pandemic |
Medicines for Europe |
19 Feb 2021 |
Health & Consumers |
|
Smarter use of generic, biosimilar and value added medicines will ensure equitable access to cancer care |
Medicines for Europe |
04 Feb 2021 |
Health & Consumers |
|
AESGP, EFPIA and Medicines for Europe reflections on the European Medicines Agency, the Heads of Medicines Agencies and the European Commission “Key principles for the use of electronic product information for EU medicines” |
Medicines for Europe |
03 Feb 2021 |
Health & Consumers |
|
Window of opportunity to enhance EU regulatory systems wide open as EU pharma strategy prioritises stronger EU networks |
Medicines for Europe |
19 Jan 2021 |
Health & Consumers |
|
EU digital strategy requires investments in the digitalisation of Europe’s medicines regulatory agencies to succeed |
Medicines for Europe |
15 Jan 2021 |
Health & Consumers |
|
EU pharma strategy success depends on access to generic, biosimilar and value added medicines |
Medicines for Europe |
25 Nov 2020 |
Health & Consumers |
|
European Health Union – first step to greater EU solidarity in health crisis situations |
Medicines for Europe |
11 Nov 2020 |
Health & Consumers |
|
Failure to launch: white paper explores the role of inappropriate use of IP in blocking access to generic and biosimilar medicines |
Medicines for Europe |
05 Nov 2020 |
Health & Consumers |
|
Now or never: pragmatism & ambition needed in EU pharma strategy to deliver on Europe’s medicines manufacturing |
Medicines for Europe |
07 Oct 2020 |
Health & Consumers |
|
Decisive action on medicines shortages should be included in pharmaceutical and industrial strategies |
Medicines for Europe |
18 Sep 2020 |
Health & Consumers |
|
COVID-19 a lightning rod for major overhaul of EU pharmaceutical policy |
Medicines for Europe |
09 Jul 2020 |
Health & Consumers |
|
IQVIA Institute Scorecards show biosimilar medicines offer win for patients, policymakers and healthcare systems across Europe |
Medicines for Europe |
30 Jun 2020 |
Health & Consumers |
|
EU Pharmaceutical Strategy Roadmap: high time to improve patient access to medicines and to apply the lessons from COVID-19 |
Medicines for Europe |
04 Jun 2020 |
InfoSociety |
|
EMA clarifies no scientific evidence to deter use of ibuprofen to manage coronavirus symptoms |
Medicines for Europe |
18 Mar 2020 |
Health & Consumers |
|
Medicines for Europe statement on COVID-19 (‘coronavirus’) |
Medicines for Europe |
13 Mar 2020 |
Health & Consumers |
|
Protecting health: Active generic and biosimilar policies central to EU pharmaceutical strategy |
Medicines for Europe |
03 Mar 2020 |
Health & Consumers |
|
The European Medicines Verification System (EMVS) celebrates 1 year of successful operation across Europe |
Medicines for Europe |
07 Feb 2020 |
Health & Consumers, InfoSociety |
|
Time to modernise the eu pharmaceutical regulatory framework to deliver on access |
Medicines for Europe |
30 Jan 2020 |
Health & Consumers, InfoSociety |
|
Smart Pharmacovigilance Essential for Patient Safety |
Medicines for Europe |
29 Jan 2020 |
Health & Consumers |
|
Generic & biosimilar medicines pivotal for safe, effective and affordable access to medicines in Europe |
Medicines for Europe |
28 Nov 2019 |
Health & Consumers |
|
‘Health revolution’: when smart innovation benefits patients |
Medicines for Europe |
21 Nov 2019 |
Health & Consumers |
|
Medicines for Europe, APOGEN and Fresenius Kabi hold Open Industry Day in Portugal |
Medicines for Europe |
14 Nov 2019 |
Health & Consumers |
|
Biosimilar medicines: competition, sustainability and early* access on the agenda of DG GROW stakeholder workshop |
Medicines for Europe |
30 Oct 2019 |
Health & Consumers |
